Crysvita यूरोपीय संघ - डेनिश - EMA (European Medicines Agency)

crysvita

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - narkotika til behandling af knoglesygdomme - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

Alminox "DAK" 500 mg + 100 mg tyggetabletter डेनमार्क - डेनिश - Lægemiddelstyrelsen (Danish Medicines Agency)

alminox "dak" 500 mg + 100 mg tyggetabletter

orifarm healthcare a/s - aluminiumaminoacetat, hydrat, magnesiumhydroxid, tungt - tyggetabletter - 500 mg + 100 mg

Link 150 mg/ml oral suspension डेनमार्क - डेनिश - Lægemiddelstyrelsen (Danish Medicines Agency)

link 150 mg/ml oral suspension

actavis group ptc ehf. - aluminiumhydroxid-magnesiumcarbonat co-prÆcipitat gel - oral suspension - 150 mg/ml

Rayaldee 30 mikrogram depotkapsler, bløde डेनमार्क - डेनिश - Lægemiddelstyrelsen (Danish Medicines Agency)

rayaldee 30 mikrogram depotkapsler, bløde

vifor fresenius medical care renal pharma france - calcifediol - depotkapsler, bløde - 30 mikrogram